Comparison of [18F]FDG and [68 Ga]pentixafor PET/CT in Nasopharyngeal Carcinoma

IF 3 4区医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Molecular Imaging and Biology Pub Date : 2024-04-16 DOI:10.1007/s11307-024-01913-1

Mengna Liu, Xi Chen, Haoyuan Ding, Qiaoqiao Shu, Yun Zheng, Yue Chen, Liang Cai

{"title":"Comparison of [18F]FDG and [68 Ga]pentixafor PET/CT in Nasopharyngeal Carcinoma","authors":"Mengna Liu, Xi Chen, Haoyuan Ding, Qiaoqiao Shu, Yun Zheng, Yue Chen, Liang Cai","doi":"10.1007/s11307-024-01913-1","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3>This study aimed to explore the feasibility of [68 Ga]pentixafor positron emission tomography/computed tomography (PET/CT) in patients with nasopharyngeal carcinoma (NPC).<h3 data-test=\"abstract-sub-heading\">Procedures</h3>This prospective study included patients with NPC who underwent [68 Ga]pentixafor PET/CT and 2-[18F]fuoro-2-deoxy-D-glucose ([18F]FDG) PET/CT within one week between November 2022 and March 2023. The [68 Ga]pentixafor and [18F]FDG uptakes in primary and metastatic lesions were measured and compared.<h3 data-test=\"abstract-sub-heading\">Results</h3>Twenty-five participants (21 patients for initial stage and four patients for recurrence detection) were enrolled in our study. The participants underwent [18F]FDG PET/CT and [68 Ga]pentixafor PET/CT. [68 Ga]pentixafor PET/CT had the same detection rate as [18F]FDG for primary tumor (96% vs. 96%). The [68 Ga]pentixafor maximum standard uptake value (SUVmax) and target-to-background ratio (TBR) of primary tumors were lower than those of [18F]FDG (SUVmax: 8.13 ± 2.78 vs. 14.25 ± 6.45; P < 0.01; TBR: 5.17 ± 2.14 vs. 9.81 ± 5.30, P < 0.01). The difference between tumor volume of [68 Ga]pentixafor (TVpentixafor) and tumor volume of [18F]FDG (TVFDG) showed no significance (median: 16.01 vs. 9.56, P = 0.332). In the detection of suspected metastatic cervical lymph nodes (CLNs), [68 Ga]pentixafor PET possessed a lower SUVmax than [18F]FDG PET/CT (SUVmax: 6.86 ± 2.63 vs. 10.39 ± 5.28, P < 0.01), but there was no significant difference in the detection rate between [68 Ga]pentixafor and [18F]FDG PET/CT (96 vs. 98, P = 0.613).<h3 data-test=\"abstract-sub-heading\">Conclusions</h3>[68 Ga]pentixafor is a promising imaging tracer for detecting primary and metastatic NPC. [68 Ga]pentixafor PET/CT is comparable to [18F]FDG PET/CT in the detection rate of primary tumors and metastatic cervical lymph nodes in nasopharyngeal carcinoma, but [68 Ga]pentixafor uptake was heterogeneous. [68 Ga]pentixafor PET/CT may help select patients most likely to benefit from CXCR4-directed endoradiotherapy.Clinical trial registration No.: ChiCTR2200065902","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Imaging and Biology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11307-024-01913-1","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

This study aimed to explore the feasibility of [⁶⁸ Ga]pentixafor positron emission tomography/computed tomography (PET/CT) in patients with nasopharyngeal carcinoma (NPC).

Procedures

This prospective study included patients with NPC who underwent [⁶⁸ Ga]pentixafor PET/CT and 2-[¹⁸F]fuoro-2-deoxy-D-glucose ([¹⁸F]FDG) PET/CT within one week between November 2022 and March 2023. The [⁶⁸ Ga]pentixafor and [¹⁸F]FDG uptakes in primary and metastatic lesions were measured and compared.

Results

Twenty-five participants (21 patients for initial stage and four patients for recurrence detection) were enrolled in our study. The participants underwent [¹⁸F]FDG PET/CT and [⁶⁸ Ga]pentixafor PET/CT. [⁶⁸ Ga]pentixafor PET/CT had the same detection rate as [¹⁸F]FDG for primary tumor (96% vs. 96%). The [⁶⁸ Ga]pentixafor maximum standard uptake value (SUV_max) and target-to-background ratio (TBR) of primary tumors were lower than those of [¹⁸F]FDG (SUV_max: 8.13 ± 2.78 vs. 14.25 ± 6.45; P < 0.01; TBR: 5.17 ± 2.14 vs. 9.81 ± 5.30, P < 0.01). The difference between tumor volume of [⁶⁸ Ga]pentixafor (TV_pentixafor) and tumor volume of [¹⁸F]FDG (TV_FDG) showed no significance (median: 16.01 vs. 9.56, P = 0.332). In the detection of suspected metastatic cervical lymph nodes (CLNs), [⁶⁸ Ga]pentixafor PET possessed a lower SUV_max than [¹⁸F]FDG PET/CT (SUV_max: 6.86 ± 2.63 vs. 10.39 ± 5.28, P < 0.01), but there was no significant difference in the detection rate between [⁶⁸ Ga]pentixafor and [¹⁸F]FDG PET/CT (96 vs. 98, P = 0.613).

Conclusions

[⁶⁸ Ga]pentixafor is a promising imaging tracer for detecting primary and metastatic NPC. [⁶⁸ Ga]pentixafor PET/CT is comparable to [¹⁸F]FDG PET/CT in the detection rate of primary tumors and metastatic cervical lymph nodes in nasopharyngeal carcinoma, but [⁶⁸ Ga]pentixafor uptake was heterogeneous. [⁶⁸ Ga]pentixafor PET/CT may help select patients most likely to benefit from CXCR4-directed endoradiotherapy.

Clinical trial registration No.: ChiCTR2200065902

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

鼻咽癌中[18F]FDG 和[68Ga]pentixafor PET/CT 的比较

目的本研究旨在探讨[68 Ga]pentixafor正电子发射断层扫描/计算机断层扫描（PET/CT）在鼻咽癌（NPC）患者中的可行性。程序本前瞻性研究纳入了在2022年11月至2023年3月期间一周内接受[68 Ga]pentixafor PET/CT和2-[18F]fuoro-2-deoxy-D-glucose（[18F]FDG）PET/CT检查的鼻咽癌患者。测量并比较了原发病灶和转移病灶的[68 Ga]pentixafor和[18F]FDG摄取量。这些患者接受了[18F]FDG PET/CT和[68Ga]pentixafor PET/CT检查。对于原发肿瘤，[68 Ga]pentixafor PET/CT 的检出率与[18F]FDG 相同（96% 对 96%）。原发性肿瘤的[68 Ga]pentixafor 最大标准摄取值（SUVmax）和靶-背景比（TBR）均低于[18F]FDG（SUVmax：8.13 ± 2.78 vs. 14.25 ± 6.45；P <；0.01；TBR：5.17 ± 2.14 vs. 9.81 ± 5.30，P <；0.01）。68 Ga]pentixafor（TVpentixafor）的肿瘤体积与[18F]FDG（TVFDG）的肿瘤体积差异无显著性（中位数：16.01 vs. 9.56，P = 0.332）。在检测疑似转移性宫颈淋巴结（CLN）时，[68 Ga]pentixafor PET的SUVmax低于[18F]FDG PET/CT（SUVmax：6.86 ± 2.63 vs. 10.39 ± 5.28，P < 0.01），但[68 Ga]pentixafor 与[18F]FDG PET/CT 的检出率无显著差异（96 vs. 98，P = 0.613）。在鼻咽癌原发肿瘤和转移性颈淋巴结的检出率方面，[68 Ga]pentixafor PET/CT与[18F]FDG PET/CT相当，但[68 Ga]pentixafor的摄取存在异质性。[68 Ga]pentixafor PET/CT可能有助于选择最有可能从CXCR4引导的放射治疗中获益的患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Molecular Imaging and Biology 医学-核医学

CiteScore

6.90

自引率

3.20%

发文量

审稿时长

3 months

期刊介绍： Molecular Imaging and Biology (MIB) invites original contributions (research articles, review articles, commentaries, etc.) on the utilization of molecular imaging (i.e., nuclear imaging, optical imaging, autoradiography and pathology, MRI, MPI, ultrasound imaging, radiomics/genomics etc.) to investigate questions related to biology and health. The objective of MIB is to provide a forum to the discovery of molecular mechanisms of disease through the use of imaging techniques. We aim to investigate the biological nature of disease in patients and establish new molecular imaging diagnostic and therapy procedures. Some areas that are covered are: Preclinical and clinical imaging of macromolecular targets (e.g., genes, receptors, enzymes) involved in significant biological processes. The design, characterization, and study of new molecular imaging probes and contrast agents for the functional interrogation of macromolecular targets. Development and evaluation of imaging systems including instrumentation, image reconstruction algorithms, image analysis, and display. Development of molecular assay approaches leading to quantification of the biological information obtained in molecular imaging. Study of in vivo animal models of disease for the development of new molecular diagnostics and therapeutics. Extension of in vitro and in vivo discoveries using disease models, into well designed clinical research investigations. Clinical molecular imaging involving clinical investigations, clinical trials and medical management or cost-effectiveness studies.